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To support the rapid growth of tumors, the cell can respond by increasing the number of mitochondria, in a concerted biosynthesis of
mitochondrial constituents (nuclear and mitochondria encoded). Increased transcription, availability and stability of oxidative phosphorylation
mRNAs, without increasing mitochondria number could also lead to more rapid energy-yielding effects. Mitochondria biogenesis and de novo
formation of respiratory chain components imply coordination of nuclear and mt gene transcription. The mitochondrial mass is regulated by a
number of physiopathological conditions. In response to external stimuli, mitochondria biogenesis is dependent on an orchestrated crosstalk
between the nuclear and the mitochondrial genomes. Based on the higher incidence of glycolysis over oxidative phosphorylation in cancer tissues,
we studied by differential proteomics the energy metabolism pathway of matched samples of normal and cancer tissue. Our results indicated that
oxidative phosphorylation in cancer cells seemed altered because there is an unbalanced coordination between nuclear- and mitochondria-encoded
mitochondrial proteins.
© 2006 Elsevier B.V. All rights reserved.Keywords: Mitochondria; Bioenergetics; Proteomics; Cancer; Differential expression1. Introduction
Cancer cells survive essentially on glycolysis whereas most
of normal cells live on oxidative phosphorylation [1–4].
Warburg – almost 80 years ago – proposed that a defect at
the mitochondrial level might be responsible for the metabolic
switch [1]. Opposite views support the notion that the rapid
growth of tumor can only be supported by anaerobic glycolysis
due to the limited availability of oxygen under these conditions.
Several mitochondrial defects have been found in cancer cells,
among them decreased ATP synthesis [2–4] and increased
mtDNAmutations [5–9]. However, these defects do not address
the main issue of cause vs. consequence: did these mitochon-
drial defects cause the onset of cancer or did mitochondria
acquire these defects as a secondary effect after the metabolic
switch towards glycolysis had been established?⁎ Corresponding author.
E-mail address: cgiulivi@ucdavis.edu (C. Giulivi).
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doi:10.1016/j.bbabio.2006.04.005To support the rapid growth of tumors, the cell can respond
by increasing the number of mitochondria, in a concerted
biosynthesis of mitochondrial constituents (nuclear and mito-
chondrial encoded) [10]. Increased transcription, availability
and stability of oxidative phosphorylation mRNAs, without
increasing mitochondria number could lead to more rapid
energy-yielding effects [11–13]. A subtle and rapid adaptation
of mitochondrial energy yield to cellular needs can be attained
by allosteric activation of oxidative phosphorylation by
metabolites such as ADP [14] or by modulation of cytochrome
c oxidase by nitric oxide [15]. Mitochondria biogenesis and de
novo formation of respiratory chain components imply
coordination of nuclear and mitochondrial gene transcription.
Levels of representative mRNAs transcribed in the two
genomes and respiratory enzyme activities under steady-state
conditions are correlated and the ratio of nuclear to mitochon-
drial mRNA expression is coordinated. However, under
pathological conditions, such as cancer, alteration of the
mitochondrial number [4,16–19] along with an increase in
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proteins [16,20–25] has been observed. However, insufficient
experimental evidences have been provided to define a
mechanism explaining the alterations at the mitochondrial
level, and from these, none are related to CRC.
The mitochondrial mass is regulated by a number of
physiopathological conditions. In response to external stimuli,
mitochondrial biogenesis is dependent on an orchestrated
crosstalk between the nuclear and the mitochondrial genomes
(Fig. 1). Recently, PGC-1α (PPARγ coactivator-1α) has been
identified as a crucial factor linking external stimuli to
modifications in mitochondrial biogenesis [26]. Lately, two
other members of the PGC-1 family have been identified: PRC
(PGC-1 related coactivator) and PGC-1β [27,28]. PRC is
ubiquitously expressed even though PGC-1α and PGC-1β are
expressed in a tissue-selective manner [29,30]. All these
coactivators interact with NRF-1 and NRF-2 (nuclear respira-
tory factors 1 and 2) that transactivate a number of genes
involved in mitochondrial functions such as oxidative phos-
phorylation, protein import, and heme biosynthesis [31]. They
also mediate mtDNA transcription and replication through two
nuclear-encoded genes: the mitochondrial transcription factor A
(Tfam) and B (mtTFB; [32,33]). If the nuclear-mitochondria
coordination is lost or altered, an accumulation/depletion of
certain component(s) would be expected, resulting in dysfunc-
tional complexes.
To address some of these issues, we focused at understanding
the biochemical differences of energy metabolism in humanFig. 1. Interplay of various transcription factors in the excolorectal cancer (CRC) and normal tissue (matched from the
same individual) by expression proteomics. Colorectal cancer
represents an ideal model system to study development and
progression of tumors because colonocytes follow a systematic
process of proliferation, differentiation and adenoma (carcino-
ma transformation). The unique opportunity of having samples
matched for each patient limited the individual variabilities; in
addition, most of the studies in CRC had been performed with
cell lines (e.g., HTC116) that may not reflect accurately the
situation in vivo [34–36].
2. Materials and methods
2.1. Chemicals and biochemicals
The Multiphor II, DryStrip kit, Immobiline DryStrips with linear pH
gradient 3–10, and Pharmalytes pH 8–10.5 and pH 3–10 were from
Amersham Pharmacia Biotech (Uppsala, Sweden); the 6000-V power supply
was purchased from Hoefer. Second-dimensional gels were cast and run in a
Blo-Rad Multi Cell. Western blotting was done using a Bio-Rad Trans-blot
apparatus (Richmond, CA, USA). Acrylamide, urea, CHAPS, DTT and
Tricine were from USB (Amersham Pharmacia Biotech); 1,4-bis-(acryloyl)
piperazine (PDA), SDS, TEMED, ammonium persulfate and nitrocellulose
membranes were from BioRad; poIyvinylidene difluoride (PVDF) and NP-40
were purchased from Boehringer (Mannheim, Germany). TRIZMA base,
agarose, thiourea, TCA, glycine, formaldehyde, silver nitrate, methanol, acetic
acid, citric acid, bicinchoninic acid (BCA) assay reagents (Pierce),
iodoacetamide and sodium deoxycholate (DOC) were from Sigma (St.
Louis, MO, USA). One-dimensional (1DGE) gels were cast and run in a
Mini-Protean II System. Western blottings were performed using Mini Trans-
Blot Transfer Cell; all remaining equipment was obtained from Bio-Rad.pression of oxidative phosphorylation components.
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2.2. Patients and tissue collection
Tissue samples were obtained from patients (4 men; 4 women; median age:
64 years; age range: 46–81 years) who had undergone surgical resection for
primary sporadic colorectal adenocarcinomas at the Department of General
Surgery, University of Florence, Italy. None of the patients had taken NSAIDs
for at least 3 months before surgery. All patients were thoroughly informed
about the study and gave written consent for the investigation in accordance with
the ethical guidelines of Local Ethical Committee.
Matched sets of coIorectal carcinomas and normal colon mucosa used for
both 1DGE and 2DGE analyses were obtained within 30 min after surgical
resection. The tissue samples were checked and sliced by a pathologist. The
diagnoses of all samples were obtained from pathology reports performed on
hematoxylin and eosin-stained tissue slices. The samples were mainly
constituted by colonocytes for these tumors were at early stages and confined
at the colon wall.
The samples of small colorectal carcinomaswere collected in distal colon and
rectum and were staged according to AJCC's classification [37]. Four tumors
were located in the distal colon, and 4 in the rectum. All eight tumors were
adenocarcinomas classified asmoderately differentiated. 1 tumorwas stage I (T2,
N0, M0); 5 were stage II (T3, N0, M0) (n=5); 2 were stage III (T2 N1, M0).
Cancer tissue (from the edge of the tumor) and adjacent normal mucosa (at least
10 cm from the tumor) were excised from each surgical specimen. The samples
were prepared for 2DGE as described in detail in ref. [38]. Staining of gels,
statistical analyses, protein identification, were performed essentially as
described before [38] with the modifications introduced by us [38] and others
[39–42].
2.3. Western blot analyses
Tumors and normal mucosa samples were homogenized in ice-cold buffer
(0.9% NaCl, 20 mM Tris–HCl, pH 7.6, 0.1% Triton X-100, 1 mM
phenylmethylsulfonyl fluoride, 0.01% leupeptin) and centrifuged at 4 °C for
10 min at 10,000×g. The protein content was determined by using a
bicinchoninic acidacid protein assay kit (Pierce Chemical Co., Rockford, IL)
with bovine serum albumin (BSA) as the standard. The samples were mixed 1:1
with Laemmli buffer under reducing conditions and boiled. Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using
12% and 5% acrylamide for the separating gel and the stacking gel, respectively.
Proteins were transferred onto nitrocellulose membranes (Pierce Chemical Co.).
Blots were blocked with 5% BSA in PBS (Pierce Chemical Co.) and incubated
overnight at 4 °C with the primary antibody. Blots were further incubated withFig. 2. A representative set of 2DGE for control and tumor tissues. Experimeappropriate secondary antibodies from Santa Cruz Biotechnology, Inc. for 1 h at
room temperature and, finally, incubated with SuperSignal West Pico
Chemiluminescent Substrate (Pierce Chemical Co.) for 5 min and then exposed
to CL Xposure Film (Pierce Chemical Co.). Western blots for human beta-
subunit of FoF1-ATPase and cytochrome c oxidase subunit II were performed
using anti-beta subunit of FoF1-ATPase (A-21351 from Molecular Probes) and
anti-COX II (A-6404 from Molecular Probes) following the manufacturer's
protocols. The blots were obtained by transferring the 2DGE of the samples and
probing sequentially (previous stripping) for the proteins. Secondary antibodies
were from Santa Cruz Biotechnology. The images were taken with Kodak
2000MM imager.3. Results and discussion
We developed a system suited to detect non-abundant
proteins in CRC. This was performed by focusing on early
stages of cancer, thus providing a more homogenous sampling,
whereas in other studies the mean of the samples originated
from cancer in stages II and III, spreading from I to IV [43].
Matched samples from each individual were processed in
parallel to minimize biological differences among samples and
technical errors for 2DGE (Fig. 2). To facilitate the detection of
low-abundant proteins, we utilized a higher loading of protein
sample (1 mg vs. 40 μg), and staining with a fluorescent dye
(more sensitive) instead of silver. Using this approach and
rigorous statistical analyses [38], we analyzed samples from
8 patients, identifying several proteins differentially expressed
in healthy and cancerous tissues. Under these conditions, we
detected 345 and 283 individual spots for normal and cancer
tissues, respectively (38; Fig. 2). To facilitate the comparison of
these tissues, multiple spots from the same protein (for example
with various posttranslational modifications) were counted only
once. This approach resulted in an average of 167±10 protein
spots in gels from normal tissues, whereas 105±12 were found
in CRC samples [38]. From these spots, we concentrated our
attention to those proteins relevant to bioenergetics.
NADH-Ubiquinone oxidoreductase B18 (a component of
Complex I) and lactic dehydrogenase (LDH) were found
overexpressed in healthy and cancer tissue, respectively,ntal details were explained under Materials and methods or in ref. [38].
Table 2
Differential protein expression regulated by NRF-1, -2, and Tfam in cancer and
normal colon tissue
Protein Upstream effector Tumor/
Control
NRF-1 NRF-2 Tfam
β−ATPasea + 0.34
Cytochrome c oxidase, subunit IIa + 2.1
δ−Aminolevulinic acid synthase + 2.6
Tfam ++ + >6
a Evaluated by Western blotting.
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Bearing in mind that LDH is a tetramer, constituted by the
combination of the M or H isoforms, the overexpressed LDH
was type 5 constituted only by M-subunits (M4). This isoform
has a low affinity for its substrates, and operates essentially
towards the formation of lactate from pyruvate, working
optimally under anaerobic conditions (as opposed to the LDH
type 1 which has high affinity for its substrates, operates
towards the formation of pyruvate from lactate under aerobic
conditions and is allosterically inhibited by pyruvate). The
biochemical properties of M4 optimize the conversion of
pyruvate to lactate to allow glycolysis to proceed under
anaerobic conditions. These results are in agreement with
several studies in which a shift in isozyme pattern from H to M
has been observed in tumors and adenocarcinomas [44].
Overexpression of mitochondrial tRNA nucleotidyltransfer-
ase and Tfam was found only in cancer tissue (Table 1). Tfam is
encoded by nDNA but controls the synthesis of mitochondrial
respiratory chain components (cytochrome c oxidase I–III,
NADH-dehydrogenase subunits 1–6, cytochrome b, and
ATPase 6 and 8) by initiating the transcription of mtDNA.
Tfam is stabilized by its interaction with mtDNA since cells
depleted of mtDNA are characterized by the absence of
detectable Tfam levels but normal levels of Tfam transcript.
High levels of Tfam protein have been associated with higher
transcript levels for some – but not all – mtDNA-encoded
proteins, not necessarily associated with protein expression in a
variety of tumors [45]. This may indicate a dysregulation at the
translational or protein level that leads to an altered content of
mtDNA-encoded proteins. To evaluate if genome origin was a
factor influencing protein expression, we explored the expres-
sion of certain proteins downstream from NRF-1, NRF-2 or
both, given that Tfam and δALAS are NRF-1 dependent,
whereas βATPase is NRF-2-dependent, and cytochrome c
oxidase II is Tfam-dependent (Table 2; Fig. 1).
Our results indicated that proteins downstream of NRF-2 had
low expression in CRC, whereas those whose upstream effector
was either NRF-1 or Tfam had higher expression. These
observations may suggest that there is a lack of coordination
between nuclear- and mitochondrial-encoded proteins in CRC.
This was evidenced by an overexpression of Tfam (nDNA-
encoded protein), cytochrome c oxidase II (mtDNA-encoded
protein) and mitochondrial tRNA nucleotidyltransferase
(nDNA-encoded protein) at the mitochondrial level and LDH
at the cytosolic level in CRC. Thus, our data may substantiate
the involvement of these genes in CRC, although mtDNATable 1
Proteins differentially expressed in normal and cancerous colon tissue
Normal Cancer
NADH-UQ
oxidoreductase B18
Lactic dehydrogenase type M
Beta-subunit of FoF1-ATPase
a Tfam1
mt tRNA nucleotidyltransferase
Cytochrome c oxidase subunit II a
a Performed by Western blotting.transcription depends not only on Tfam but also on other factors
(see below). Increased levels of Tfam and NRF-1 have been
previously shown to occur concurrently with increased protein
levels of nuclear and mitochondrial subunits of respiratory
Complex IV [46]; however, in this study, cytochrome c oxidase
II showed only a 2-fold increase compared to the significantly
higher overexpression of Tfam in CRC. An alternative
explanation could be that the increase of Tfam leads to a
decreased mtDNA replication. The D-loop in mtDNA is the
characteristic triple-strand structure stabilized by the Tfam
association involved in the regulation of mtDNA replication
[47]. It could be speculated that the increase in Tfam levels
leads mainly to an accumulation of short D-loops that abort
mtDNA replication. This hypothesis is supported by a study in
which the increase of a novel RNA species derived from the D-
loop in immortal cells is increased [48].
In control tissue, NADH-UQ oxidoreductase B18 (nDNA-
encoded protein) and βATPase (nDNA-encoded) were found
overexpressed. Thus, assuming that mtDNA integrity has been
preserved (for Tfam levels parallel the levels of mtDNA; 49),
transcription and translation processes of mtDNA-encoded
proteins are responsive to Tfam levels (for the expression of mt
tRNA nucleotidyltransferase, required for tRNA maturation,
and cytochrome c oxidase II are increased, whereas an NRF2-
dependent protein – such as βATPase – was decreased), it is
suggested that the NRF-2 pathway could be affected at the
levels of transcription, translation, or protein levels. Although
NRF-1 and NRF-2 contribute to the gene activation of Tfam,
NRF-1 binding seems to be the major determinant of promoter
function, thus reinforcing the concept that the NRF-2 pathway
seems to be altered.
This postulate may provide the first molecular change that
results in the “respiratory impairment” of cancer cells postulated
by Warburg [1]. An early change in the NRF-2 pathway – not
matched by NRF-1 or Tfam – may ensue in dysfunctional
mitochondria with an altered ratio of electron transport carriers.
The lack of functional mitochondria would lead to the
invariably high ratio of fermentation to respiration typical of
cancer metabolism. This switch to glycolysis would ensure a
supply ATP even before hypoxic conditions – which usually
accompany cancer growth at later stages – had been established.
4. Conclusions
We were able to identify several, low-abundant proteins
differentially expressed in cancer and normal colon tissues.
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an insight into the mechanism of the prevalence of glycolysis
use over oxidative phosphorylation. Here, we focused on the
main known activators and coactivators of mitochondrial
biogenesis, especially those found relevant in other tumors. It
is premature to speculate that NRF-1 and NRF-2 elements
define mutually exclusive sets of nuclear-encoded respiratory
genes [50] for it has been found that both the NRF-1-dependent
cytochrome c promoter and the NRF-2-dependent cytochrome c
oxidase IV promoter have in common stimulation by Sp1
binding sites [51]. Other factors such as CREB and YY1 could
also be responsible for the activation (of part) of these pathways.
Other mechanisms that could be explored are the following:
transcript stabilization [52], posttranscriptional regulation of
Tfam [49], and cis-acting elements on the 3′-UTR of the β-
ATPase transcript [52]. Our lab is currently exploring these
alternative pathways.
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